间质性肺疾病患者对肺炎球菌疫苗的应答:全身免疫抑制治疗的影响
研究纳入门诊规律随访的间质性肺疾病(ILD)患者,于接种肺炎球菌疫苗前及接种后4-8周采集血清,用ELISA检测针对血清型19F的IgG浓度。结果显示各组接种后IgG浓度均升高,首次接种者中PCV13与PPSV23均诱导IgG升高;ILD组应答率与接受糖皮质激素治疗的ILD组相当,仅接受免疫抑制治疗的特发性肺纤维化患者应答显著降低。
要点
- ILD患者接种肺炎球菌疫苗后针对血清型19F的IgG浓度在各组均升高。
- 首次接种者中PCV13与PPSV23均能诱导IgG浓度升高。
- 仅接受免疫抑制治疗的特发性肺纤维化患者应答显著降低。
核心结论
- ILD患者接种肺炎球菌疫苗后IgG浓度均升高,ILD组应答率与接受糖皮质激素治疗的ILD组相当,仅接受免疫抑制治疗的特发性肺纤维化患者应答显著降低。
研究设计与样本
- 纳入门诊规律随访的间质性肺疾病(ILD)患者,于接种前及接种后4-8周采集血清,用ELISA检测针对肺炎球菌血清型19F的IgG浓度。
主要发现
- 针对血清型19F的IgG浓度在接种后所有组均升高。
- 首次接种者中PCV13与PPSV23均诱导IgG浓度升高。
- ILD组应答率与接受糖皮质激素治疗的ILD组相当。
- 仅接受免疫抑制治疗的特发性肺纤维化患者应答显著降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung diseases (ILD) are severe respiratory diseases, and ILD patients are treated with corticosteroid and immunosuppressive agents. However, it is unclear whether these medications influence the response of pneumococcal vaccine. OBJECTIVES: We examined the immunogenicity of pneumococcal vaccines (PPSV23 and PCV13) in ILD patients undergoing immunosuppressive treatment. METHODS: ILD patients who were regularly followed at the outpatient clinic were enrolled. Sera were collected before and 4-8 weeks after vaccination. Serotype-specific immunoglobulin G (IgG) concentrations against pneumococcal serotype 19F were measured by ELISA. RESULTS: IgG concentrations to serotype 19F were increased in all groups in response to the vaccine. Both PCV13 and PPSV23 induced IgG concentrations in patients immunized for the first time. Response rates for the ILD group were comparable with those for the ILD group undergoing corticosteroid therapy. Only idiopathic pulmonary fibrosis patients undergoing immunosuppressive therapy had a significantly lower response.
引用
- Kuronuma K, Honda H, Mikami T, et al. Response to pneumococcal vaccine in interstitial lung disease patients: Influence of systemic immunosuppressive treatment. Vaccine. 2018. PMID: 29983256. doi:10.1016/j.vaccine.2018.06.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。